Advancements in RP-HPLC: A Review on the Simultaneous Determination of Simvastatin and Celecoxib in Plasma
DOI:
https://doi.org/10.52783/jns.v14.3203Keywords:
RP-HPLC,, simvastatin, celecoxib, therapeutic drug monitoring, pharmacokinetics, drug interactionAbstract
People use simvastatin alongside celecoxib routinely because physicians prescribe these drugs for cardiovascular and inflammatory condition management. Scientists need precise measurement of these drugs in plasma because it enables better therapeutic benefits while reducing unwanted side effects. The analysis of both simvastatin and celecoxib in plasma by Reverse Phase High-Performance Liquid Chromatography (RP-HPLC) undergoes a complete review regarding development and validation, as well as practical implementation. The high sensitivity, along with selectivity and precision characteristics of RP-HPLC, make it an excellent tool for plasma concentration analysis of these drugs. Method development requires optimization of mobile phase composition alongside column selection and detection wavelength, together with flow rate identification. The RP-HPLC method proved suitable for both research and clinical work by validating its performance measures for accuracy, precision, LOD and LOQ, sensitivity and linearity and robustness, and specificity. RP-HPLC stands as an essential technique in the evaluation of drug pharmacokinetics and therapeutic drug monitoring, and drug interaction tests. Visiting RP-HPLC enables researchers to obtain critical data about how simvastatin and celecoxib move through the body through absorption and distribution and metabolism, and elimination (ADME) processes. The data obtained from therapeutic drug monitoring using RP-HPLC allows medical professionals to optimize drug treatment by modifying patient doses based on plasma drug levels. RP-HPLC plays an essential role in the identification of synergistic reactions among medications when patients use several drugs at once. The implementation of RP-HPLC creates several difficulties since it deals with matrix interference and sensitivity problems, and operational limitations. Advancements in column technology combined with mobile phase optimization techniques and modern detection methods via mass spectrometry will significantly improve RP-HPLC utility and accessibility in clinical practice.
Downloads
Metrics
References
Jiang W, Hu J-W, He X-R, Jin W-L, He X-Y. Statins: a repurposed drug to fight cancer. Journal of Experimental & Clinical Cancer Research. 2021;40(1):241.
Shi Z, Han S. Personalized statin therapy: Targeting metabolic processes to modulate the therapeutic and adverse effects of statins. Heliyon. 2025;11(1):e41629.
Khatiwada N, Hong Z. Potential Benefits and Risks Associated with the Use of Statins. Pharmaceutics. 2024;16(2):214.
Rawat C, Kukal S, Dahiya UR, Kukreti R. Cyclooxygenase-2 (COX-2) inhibitors: future therapeutic strategies for epilepsy management. Journal of Neuroinflammation. 2019;16(1):197.
Brune K, Neubert A. Pharmacokinetic and pharmacodynamic aspects of the ideal COX-2 inhibitor: A pharmacologist's perspective. Clinical and experimental rheumatology. 2001;19:S51-7.
Dunn SP, Holmes DR, Moliterno DJ. Drug–Drug Interactions in Cardiovascular Catheterizations and Interventions. JACC: Cardiovascular Interventions. 2012;5(12):1195-208.
Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE. Celecoxib pathways: pharmacokinetics and pharmacodynamics. Pharmacogenet Genomics. 2012;22(4):310-8.
Puszkiel A, Noé G, Boudou-Rouquette P, Cossec C, Jennifer A, Giraud J-S, et al. Development and validation of an ELISA method for the quantification of nivolumab in plasma from non-small-cell lung cancer patients. Journal of Pharmaceutical and Biomedical Analysis. 2017;139.
Alhajj M, Zubair M, Farhana A. Enzyme-Linked Immunosorbent Assay. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
Naidu R, Kale U, Shingare M. Stability indicating RP-HPLC method for simultaneous determination of amlodipine and benzapril hydrochloride from their combination drug product. Journal of pharmaceutical and biomedical analysis. 2005;39:147-55.
Gumułka P, Żandarek J, Dąbrowska M, Starek M. UPLC Technique in Pharmacy—An Important Tool of the Modern Analyst. Processes. 2022;10(12):2498.
Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R, et al. Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. Int J Oncol. 2017;51(3):931-8.
Tome T, Casar Z, Obreza A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules (Basel, Switzerland). 2020;25.
Tome T, Časar Z, Obreza A. Development of a Unified Reversed-Phase HPLC Method for Efficient Determination of EP and USP Process-Related Impurities in Celecoxib Using Analytical Quality by Design Principles. Molecules. 2020;25(4).
Marques Marinho F. Development and Validation of an RP-HPLC Method for Simvastatin Capsules. Current Pharmaceutical Analysis. 2013;9:2-12.
Tome T, Žigart N, Časar Z, Obreza A. Development and Optimization of Liquid Chromatography Analytical Methods by Using AQbD Principles: Overview and Recent Advances. Organic Process Research & Development. 2019;23(9):1784-802.
Aljammal K. Development and Validation of Micro Emulsion High Performance Liquid Chromatography(MELC) Method for the Determination of Nifedipine in Pharmaceutical Preparation. Pharmaceutica Analytica Acta. 2015;06.
Mahadevarao Premnath S, Zubair M. Chromatography. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2025, StatPearls Publishing LLC.; 2025.
Djajić N, Krmar J, Rmandić M, Rašević M, Otašević B, Zečević M, et al. Modified aqueous mobile phases: A way to improve retention behavior of active pharmaceutical compounds and their impurities in liquid chromatography. Journal of Chromatography Open. 2022;2:100023.
Dey S, De A, Mandal S, Pradhan P, Patel C, Shah S, et al. DEVELOPMENT AND VALIDATION OF RP-HPLC METHOD FOR THE ESTIMATION OF SIMVASTATIN IN BULK AND PHARMACEUTICAL DOSAGE FORM. 2013:3.
Žuvela P, Skoczylas M, Liu J, Ba̧czek T, Kaliszan R, Wong M, et al. Column Characterization and Selection Systems in Reversed-Phase High-Performance Liquid Chromatography. Chemical Reviews. 2019;119.
Attimarad M, Venugopala KN, Sreeharsha N, Chohan MS, Shafi S, Nair AB, et al. A Rapid HPLC Method for the Concurrent Determination of Several Antihypertensive Drugs from Binary and Ternary Formulations. Separations. 2021;8(6):86.
Alphonse M, Nesrine L. Experimental design methodology for optimization and robustness determination in ion pair RP-HPLC method development: Application for the simultaneous determination of metformin hydrochloride, alogliptin benzoate, and repaglinide in tablets. Microchemical Journal. 2019;147.
Agrahari V, Bajpai M, Nanda S. Essential Concepts of Mobile Phase Selection for Reversed Phase HPLC. Research Journal of Pharmacy and Technology. 2013;6:459-64.
Tripathi DA, Dewani A, Chandewar A, Mazumder PM. Approaches development and validation of RP-HPLC method for estimation of glimepiride in rat plasma-application to pharmacokinetic studies. 2016;11:55-61.
Eveque-Mourroux MR, Emans PJ, Boonen A, Claes BSR, Bouwman FG, Heeren RMA, et al. Heterogeneity of Lipid and Protein Cartilage Profiles Associated with Human Osteoarthritis with or without Type 2 Diabetes Mellitus. Journal of Proteome Research. 2021;20(5):2973-82.
Badawy MEI, El-Nouby MAM, Kimani PK, Lim LW, Rabea EI. A review of the modern principles and applications of solid-phase extraction techniques in chromatographic analysis. Analytical Sciences
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
